# Irinotecan Combination Chemotherapy for Refractory or Relapsed Brain Tumor in Children and Adolescents

> **NCT01535183** · PHASE2 · UNKNOWN · sponsor: **Seoul National University Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Brain Tumor

## Interventions

- **DRUG:** Irinotecan combination chemotherapy

## Key facts

- **NCT ID:** NCT01535183
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-01
- **Primary completion:** 2016-09
- **Final completion:** 2016-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2014-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01535183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01535183, "Irinotecan Combination Chemotherapy for Refractory or Relapsed Brain Tumor in Children and Adolescents". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01535183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*